Trispecific antibody targeting HIV-1 and T cells activates and eliminates latently-infected cells in HIV/SHIV infections.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
22 06 2023
22 06 2023
Historique:
received:
04
08
2022
accepted:
30
05
2023
medline:
26
6
2023
pubmed:
23
6
2023
entrez:
22
6
2023
Statut:
epublish
Résumé
Agents that can simultaneously activate latent HIV, increase immune activation and enhance the killing of latently-infected cells represent promising approaches for HIV cure. Here, we develop and evaluate a trispecific antibody (Ab), N6/αCD3-αCD28, that targets three independent proteins: (1) the HIV envelope via the broadly reactive CD4-binding site Ab, N6; (2) the T cell antigen CD3; and (3) the co-stimulatory molecule CD28. We find that the trispecific significantly increases antigen-specific T-cell activation and cytokine release in both CD4
Identifiants
pubmed: 37349337
doi: 10.1038/s41467-023-39265-z
pii: 10.1038/s41467-023-39265-z
pmc: PMC10287722
doi:
Substances chimiques
HIV Antibodies
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3719Informations de copyright
© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.
Références
Curr HIV Res. 2021;19(1):14-26
pubmed: 32819259
Nat Rev Microbiol. 2014 Nov;12(11):750-64
pubmed: 25402363
J Exp Med. 2017 Apr 3;214(4):959-972
pubmed: 28341641
N Engl J Med. 1998 Mar 26;338(13):853-60
pubmed: 9516219
Nature. 2020 Feb;578(7793):154-159
pubmed: 31969705
Nat Cancer. 2020 Jan;1(1):86-98
pubmed: 35121834
Nature. 2012 Jul 25;487(7408):439-40
pubmed: 22836995
J Virus Erad. 2019 Jan 1;5(1):50-59
pubmed: 30800428
Antimicrob Agents Chemother. 2019 Oct 22;63(11):
pubmed: 31501143
Can J Public Health. 2012 May-Jun;103(3):202-6
pubmed: 22905639
Nat Med. 2014 Apr;20(4):425-9
pubmed: 24658076
Lancet. 2003 Jul 5;362(9377):22-9
pubmed: 12853195
Science. 1998 Dec 18;282(5397):2266-9
pubmed: 9856952
Eur J Immunol. 2008 Jun;38(6):1522-32
pubmed: 18446791
Proc Natl Acad Sci U S A. 2014 May 13;111(19):7078-83
pubmed: 24706775
J Clin Invest. 2021 Apr 15;131(8):
pubmed: 33630764
Front Microbiol. 2017 Jun 07;8:1035
pubmed: 28638377
Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):185-90
pubmed: 9874793
PLoS One. 2013 Dec 18;8(12):e81355
pubmed: 24367482
Science. 1999 Jan 29;283(5402):680-2
pubmed: 9924026
J Virol. 2018 Jun 13;92(13):
pubmed: 29643247
Science. 1997 Nov 14;278(5341):1295-300
pubmed: 9360927
Nat Rev Immunol. 2022 Aug;22(8):499-512
pubmed: 34824401
Immunity. 2018 May 15;48(5):872-895
pubmed: 29768175
J Virol. 2020 Oct 14;94(21):
pubmed: 32817214
Nature. 2020 Feb;578(7793):160-165
pubmed: 31969707
Annu Rev Med. 2018 Jan 29;69:421-436
pubmed: 29099677
PLoS Pathog. 2021 Feb 18;17(2):e1009339
pubmed: 33600506
Blood. 2007 Dec 15;110(13):4161-4
pubmed: 17881634
PLoS Pathog. 2013;9(12):e1003834
pubmed: 24385908
PLoS Pathog. 2017 Mar 22;13(3):e1006283
pubmed: 28328934
FEBS J. 2016 Sep;283(18):3325-34
pubmed: 27191544
Nat Commun. 2015 Oct 20;6:8447
pubmed: 26485194
AIDS. 2014 May 15;28(8):1193-202
pubmed: 24556869
Retrovirology. 2011 Oct 12;8:80
pubmed: 21992606
Sci Transl Med. 2017 Jan 18;9(373):
pubmed: 28100833
Lancet. 2003 Oct 18;362(9392):1267-74
pubmed: 14575971
Retrovirology. 2013 Oct 24;10:119
pubmed: 24156240
Nat Commun. 2016 Sep 08;7:12731
pubmed: 27605062
Immunity. 1996 Jun;4(6):527-34
pubmed: 8673699
J Virol. 2020 Sep 15;94(19):
pubmed: 32669328
iScience. 2022 Sep 05;25(10):105067
pubmed: 36157588
JCI Insight. 2019 Jun 6;4(11):
pubmed: 31167974
Science. 2010 Aug 13;329(5993):856-61
pubmed: 20616233
Nat Immunol. 2015 Jun;16(6):584-9
pubmed: 25990814
Cell Host Microbe. 2018 Jan 10;23(1):14-26
pubmed: 29324227